Consequently, FDA and EMA approved osimertinib for the treatment of patients with metastatic EGFR-mutated NSCLC with an acquired T790M mutation after progression on previous EGFR-TKI therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.